Allergen immunotherapy in house dust mite-associated allergic rhinitis: efficacy of the 300 IR mite tablet

Abstract Background A perennial house dust mite-associated allergic rhinitis has a major impact on the quality of life patients and is associated with high socioeconomic burden. The most common symptoms include runny nose nasal congestion, sneezing, itching nose, mouth and/or throat, ocular symptoms. Affected often develop bronchial asthma. Therapy options for allergen avoidance, symptomatic treatment, immunotherapy. Allergen immunotherapy only disease-modifying treatment that can permanently alleviate rhinitis. In July 2021, new sublingual mite tablet was approved in Germany. Methods This review summarizes clinical studies 300 IR (index reactivity) adolescents adults presents results. Results phase II III considered here, different dosages were investigated. showed best benefit–risk profile been Europe, Japan, South Korea, Australia, New Zealand Conclusion an effective relieves symptoms, reduces need medication, improves both At same time, well tolerated. Mild to moderate reactions at application site subside after few days.